CRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The company and partner Vertex Pharmaceuticals delivered positive results from clinical trials of their blood disorders candidate, exa-cel, and investors bet on potential regulatory approvals to follow.

In recent weeks, investors won that bet. Regulators in the U.K. authorized exa-cel -- to be commercialized as Casgevy -- for sickle cell disease and beta thalassemia. U.S. regulators approved the gene-editing treatment for sickle cell and aim to issue a decision on the second blood disorder early next year.

All of this marks just the beginning of a great opportunity for long-term investors. Let's check out three reasons to buy CRISPR Therapeutics like there's no tomorrow.

Continue reading

Source Fool.com